Focused Ultrasound for Gene and Cell Therapy Workshop Participants
In-Person Workshop Attendees
Listed Alphabetically by Last Name
Karen Aboody, MD
Professor, Department of Stem Cell Biology and Regenerative Medicine
Scientific Leader, Neuro-Oncology Disease Team
City of Hope National Medical Center & Beckman Research Institute
Dr. Aboody received her MD from Mount Sinai School of Medicine and completed her post-doctoral training in Molecular Neurogenetics at Massachusetts General Hospital, Harvard Medical School, where she discovered the tumor-tropic properties of neural stem cells (NSCs). She has been internationally renowned as a pioneer in this field since her seminal publication in the Proceeding of the National Academy of Sciences (PNAS) in 2000. She joined City of Hope in 2003 to head a translational stem cell-oncology research laboratory focused on using NSCs to selectively deliver therapeutic payloads to invasive and metastatic solid tumors. She is at the forefront of stem cell targeted cancer therapies, with 4 first-in-human phase I clinical trials for high-grade glioma patients. Therapeutic strategies include enzyme/prodrug gene therapies and oncolytic viro-immunotherapy. Her team is currently investigating potential applications of NSC targeted treatment for metastatic cancers. She has also recently been investigating the use low intensity focused ultrasound (LIFU) to target i.v. delivered stem cell exosomes to the brain, as an anti-inflammatory therapeutic for central nervous system degenerative disorders, including chemobrain.
Raag Airan, PhD, MD
Stanford University School of Medicine
Raag Airan MD, PhD is a clinical neuroradiologist at Stanford University and directs a laboratory developing and clinically translating technologies for focused ultrasound targeted drug and gene delivery, and ultrasonic glymphatic modulation.
Jose Amich, MBA
Co-Founder & CEO
Zeta Surgical, Inc.
Jose Amich is a graduate of Harvard University, and part of the MIT Sloan MBA deferred admission program. Prior to Z Imaging, Jose was a research fellow at Harvard Medical School studying breast cancer. He also co-founded Dotacle Technologies, where he led a clinical study with the Massachusetts General Hospital in Western Kenya to evaluate the efficacy of a novel low-cost visual aid system.
Costas Arvanitis, PhD
Georgia Institute of Technology
Dr Arvanitis is a joint Assistant Professor at the Woodruff School of Mechanical Engineering and the Coulter Department of Biomedical Engineering at Georgia Institute of Technology and Emory University. Dr Arvanitis research program is focused on ultrasound biophysics and bioengineering and its overarching goal is the discovery and translation to the clinics of novel therapeutic interventions against human disease. His lab is particularly active in the field of brain research, where they investigate ultrasound meditated mass transport and drug delivery in the brain and develop computational tools to support the more rational design of focused-ultrasound-based treatment of brain cancer.
Sunnybrook Health Sciences Centre
Isabelle Aubert obtained her PhD from the Department of Neurology & Neurosurgery at McGill University. As a post-doctoral fellow at the Salk Institute for Biological Studies, she developed regenerative gene therapy approaches for the aging brain. Currently, she works as a Senior Scientist at Sunnybrook Research Institute and a Professor at the University of Toronto. Dr. Aubert holds a Tier 1 Canada Research Chair in Brain Repair and Regeneration and is an elected Fellow of the Canadian Academy of Health Sciences.
Through collaborative work, she leads the Brain Repair Group at Sunnybrook. The team uses ultrasound-mediated blood-brain barrier modulation, with and without exogenous therapeutics, to reduce pathology and improve brain plasticity, regeneration, and function in animal models of neurodegenerative disorders. For over a decade, non-invasive gene delivery to the brain using recombinant adeno-associated viruses and focused ultrasound has been central to Dr. Aubert’s research program. In building partnerships, Dr. Aubert aims to bring the potential of focused ultrasound-mediated gene therapy to patient populations.
Professor & Co-chief of Functional Neurosurgery
Alec Batts is currently a PhD candidate under the guidance of Dr. Elisa Konofagou in the Department of Biomedical Engineering at Columbia University. One of Alec’s active research aims is centered around using novel platforms for focused ultrasound-facilitated blood-brain barrier opening for viral vector-mediated gene delivery in experimental models of Parkinson’s disease and Huntington’s disease.
Javier Blesa, PhD
Centro Integral de Neurociencias (CINAC), HM Hospitales
Javier Blesa was graduated in Biochemistry and Biology at the University of Navarra, Spain. He obtained a PhD in Neurosciences from the Center for Applied Medical Research (CIMA) under the expert guidance of Dr. Jose A. Obeso. During his PhD he attained grants to join Dr. Thomas Wichmann lab (Emory University, Atlanta) and Dr. Oleh Hornykiewicz (Univ. Vienna) lab as well. After obtaining his PhD, he obtained the fellowship from the Spanish Minister of Education, and he moved to New York to the lab of Dr. Serge Przedborski at Columbia University. After 4 years at Columbia, he joined the lab of Dr. Paul Greengard (2000 Nobel Prize in Physiology or Medicine) at Rockefeller University in New York until he moved back to Spain to join the new Centre for Integrative Research in Madrid as a Research Scientist. He is member of the Editorial Board of Neurobiology and Disease and Frontiers of Neuroanatomy and ad hoc reviewer of top neuroscience journals. He is author or co-author of more than 55 publications in the field of Parkinson’s disease in top journals like Nature Reviews Neuroscience, Nature Neuroscience, Neuron, Science Advances, Molecular Therapy or Annals of Neurology (H factor=28; >6300 cites). He has served as expert evaluator for the European Commission, the French National Research Agency (FRA), the Dutch Research Council (NOW), the Luxembourg National Research Fund (FNR), and other national public and private entities. In the last years he has been honored to receive the “Marie Sklodowska-Curie Actions Seal of Excellence” and The Alpha&Omega Prize for young researchers, and different funding from public and private institutions.
Catherine Bollard, MD
Children’s National Hospital
Dr. Bollard received her medical degree at the University of Otago in Dunedin, New Zealand. She is board certified both in pediatrics and hematology. She worked in New Zealand and London, England, before moving to Houston, Texas, in 2000 where she was a Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine (BCM). In August 2013, she was recruited to Washington, DC, to join Children’s National Hospital and George Washington University. She is the Bosworth Chair for Cancer Biology, Director of the Center for Cancer and Immunology Research, and Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) at Children’s National Hospital. She is a Professor of Pediatrics and of Microbiology, Immunology, and Tropical Medicine at George Washington University and the Associate Center Director for Translational Research and Innovation at the GW Cancer Center. Dr. Bollard is a member of the American Society for Clinical Investigation, is a past president of the International Society for Cellular Therapy, and the current President of the Foundation for the Accreditation of Cellular Therapy. She was an associate editor for the journal Blood from 2014-2021 and is currently Editor in Chief of Blood Advances. She has >200 peer reviewed publications and has been independently NIH funded for over a decade. Her bench and translational research focuses on improving outcomes for patients after transplant and on the development of novel cell therapies for cancer and virus-associated diseases.
Senior Principal Engineer
Mayumi is a Senior Principal Engineer in the Pharma Technical Development, Device & Packaging Development at Genentech, A Member of the Roche Group. She has +25 years of experience and a broad range of expertise in R&D, cGMP, and commercialization for biologics, drugs, and combination products development including drug formulation, drug delivery system, process engineering, and sterilization development in the Biopharmaceutical and Pharmaceutical industries.
Philip (P.J.) Brooks, PhD
Deputy Director, Division of Rare Diseases Research Innovation
National Institutes of Health
Philip J. (P.J.) Brooks is the acting director of NCATS’ Division of Rare Diseases Research Innovation. Brooks represents NCATS in the NIH-wide Gene Therapy Working Group, the Regenerative Medicine Innovation Project and the International Rare Diseases Research Consortium (IRDiRC). He also is the working group co-coordinator for the NIH Common Fund program on Somatic Cell Genome Editing, one of the leaders of the Platform Vector Gene Therapy (PaVe-GT) pilot project and the co-chair of the Bespoke Gene Therapy Consortium. In May 2022, Brooks was selected as the recipient of the 2022 Sonia Skarlatos Public Service Award by the American Society of Gene & Cell Therapy for consistently fostering and enhancing the field of gene and cell therapy. Brooks received his doctorate in neurobiology from The University of North Carolina at Chapel Hill. After completing a postdoctoral fellowship at The Rockefeller University, he became an investigator in the NIH intramural program, where he developed an internationally recognized research program focused on two distinct areas: the molecular basis of alcohol-related cancer, and rare neurologic diseases resulting from defective DNA repair, including xeroderma pigmentosum, Cockayne syndrome and Fanconi anemia.
Diane Carlisle, PhD
University of Pittsburgh Medical Center
Diane Carlisle PhD is an Associate Professor in the University of Pittsburgh Department of Neurological Surgery. Her research program focuses identifying new therapeutic targets and developing pharmacologic therapies in neurodegenerative diseases, including Huntington’s Disease, ALS, and age-related dementia. Her research program incorporates focus ultrasound to open the blood brain barrier to improve brain distribution of potential therapeutics.
Bradford Casey, PhD
The Michael J. Fox Foundation for Parkinson’s Research
Bradford Casey, Ph.D., Senior Associate Director in the Fox Foundation’s Discovery and Translational Research division, leads the Foundation’s Genomics, Computational Biology, and Data Science research portfolios. He collaborates with academic, industry, and clinical researchers to manage and develop MJFF’s global research portfolio and ensure that MJFF research priorities and resources reflect and best serve the ultimate needs of patients. He routinely engages with key experts across disciplines to identify and develop new approaches to address gaps in the field, and to establish strategic partnerships. In addition to academic research, Bradford has diverse experience working with researchers, legislators, and government agencies on initiatives to advocate for and support neuroscience research.
Bradford is passionate about leveraging emerging technologies to improve biomedical research, and achieving the Foundation’s mission to understand and treat Parkinson’s disease.
Parwathy Chandran, PhD
U.S. Food and Drug Administration
Pharmacology/Toxicology Reviewer at Office of Pharmacology/Toxicology (OPT), Center for Biologics Evaluation and Research (CBER), FDA.
James Choi, PhD
Senior Lecturer (Associate Professor)
Imperial College London
Dr. Choi develops focused ultrasound and microbubble technologies for safer
and more robust blood-brain barrier opening. He works on all aspects of the
technology, including better pulse sequences, microbubbles, ultrasound
arrays of emitters and sensors, driving engines, and mechanistic studies.
Dr. Choi also performs pre-clinical studies on animals for diseases, such as
Alzheimer’s disease, giloblastoma multiforme, and diffuse midline glioma.
Dr. Kuldip Dave is Senior Vice President of Research and joined The ALS Association in May 2019. In this role, he leads the world’s largest philanthropic research funding program for ALS. He develops and implements the broader research vision by setting annual priorities and department goals including research funding strategy, research programs, and strategic initiatives and is also responsible for the operational, staffing, and budgetary oversight of the research program. Dr. Dave received his bachelor’s degree in biology from Rutgers University. He received his Ph.D. degree in Pharmacology and Physiology from Drexel University College of Medicine in Philadelphia. He went on to work for pharmaceutical industry for 5 years before joining The Michael J. Fox Foundation for Parkinson’s research. After nine years at MJFF, he joined the ALS Association as the head of the Research program.
Yves DeKoninck, PhD, FCAHS, FRSC
Yves De Koninck Laboratory
Yves De Koninck, PhD, FCAHS, FRSC is Professor of Psychiatry & Neuroscience at Université Laval, Scientific Director of the CERVO Brain Research Centre and Director of Research of the Quebec Integrated University Health and Social Services Centre. Former President of the Canadian Association for Neuroscience, he founded the Quebec Pain Research Network. He is a fellow of the Canadian Academy of Health Sciences and of the Royal Society of Canada. He holds a Canada Research Chair in Chronic Pain and Related Brain Disorders. His main areas of research include chronic pain, drug dependence, cognitive ageing, and neurodegenerative disorders. He founded the Neurophotonics Centre (neurophotonics.ca), bringing together physicists, engineers, mathematicians, and biologists to stimulate technology development to probe the brain. He now leads Sentinel North a global initiative to harness the power of light for the benefit of health, environment, and sustainable development in the North. He currently leads the Canadian Brain Research Strategy. Accolades include the Distinguished Career Award from the Canadian Pain Society, the Emily Gray Award from the Biophysical Society and the Award for Education in Neuroscience from the Society for Neuroscience.
University of Virginia
Anna Debski is a fourth year PhD student in the Price Lab at the University of Virginia. Her research focuses on developing non-viral gene delivery platforms for glioblastoma multiforme (GBM). She is also investigating effects of CRISPR-mediated P-glycoprotein knockdown for enhanced therapeutic delivery in GBM. Previously, she received a bachelor of science degree in Materials Science and Engineering at the Ohio State University.
Ben Deverman, PhD
Broad Institute of MIT and Harvard
Ben Deverman is the Senior Director of Vector Engineering and an Institute Scientist at the Broad Institute of MIT and Harvard. Ben’s laboratory in the Stanley Center for Psychiatric Research at the Broad Institute develops and applies novel high-throughput screens and data-driven protein and genome engineering techniques to create more efficient and targeted AAV vectors to advance gene therapy and support scientific discovery. In prior work at the California Institute of Technology, Ben and colleagues identified numerous capsids, including AAV-PHP.B and an enhanced variant, AAV-PHP.eB, that made efficient brain-wide gene delivery possible for the first time.
Bradford Elmer, PhD
Brad Elmer, PhD is a Lab Head and Principal Scientist in the Genomic Medicine Unit at Sanofi. He trained as a neuroscientist studying mechanisms of synapse formation and brain development at the University of California, Davis and at Cold Spring Harbor Labs. He has spent the last 9 years at Sanofi, with a focus on developing gene therapies for the treatment of neurodegenerative diseases.
Esteban Engel, PhD
Esteban is Director of Neuroscience Platform Technology Research at Spark Therapeutics in Philadelphia. Esteban has over 40 publications in peer-reviewed journals and patent applications dealing with viral-based gene therapies. Prior to joining Spark Therapeutics, he was a Principal Investigator and Group Leader at the Princeton University Neuroscience Institute, developing neurotropic viral vectors for gene transfer, and to diseect mamalian brain connectivity and function. He was the co-Director of the NIH-funded Center for Neuroanatomy with Neurotropic Viruses (CNNV). Esteban has trained over 20 undergraduate students, graduate students and postdoctoral fellows and have obtained private, State, and Federal research grants.
Mario Fabiilli, PhD
Research Associate Professor
University of Michigan
Dr. Mario Fabiilli is an Associate Professor of Radiology and Biomedical Engineering at the University of Michigan. His lab develops ultrasound-based therapies with a focus on biomaterials for drug delivery and tissue regeneration, including strategies for blood vessel and bone growth.
Kathy Ferrara, PhD
Professor of Radiology and Division Chief, Molecular Imaging
Dr. Ferrara is Professor of Radiology and Division Chief of the Molecular Imaging Program at Stanford University. She previously served as the founding chair of the Department of Biomedical Engineering at UC Davis. Dr. Ferrara is a member of the National Academy of Engineering and a fellow of the American Association for the Advancement of Science, Institute of Electrical and Electronic Engineers, Biomedical Engineering Society, Acoustical Society of America, World Molecular Imaging Society and American Institute of Medical and Biological Engineering. Her publications include 300 manuscripts in the area of image-guided drug and gene delivery.
Jonathan Fischell, MD, MSc
National Institute of Neurology
Master’s degree at University of Maryland studied rapidly acting antidepressant compounds in rat model using electrophysiology and behavioral methods. Medical school at University of Maryland. Became interested in gene therapy for neurodegenerative diseases. Neurology residency at University of Maryland, worked in lab producing AAVs for intra-arterial delivery in mice. Fellowship at NIH. Lab research includes studying effects of genetic modifications of alpha-synuclein in human iPSC derived dopaminergic neuron model of Parkinson’s disease using a multi-omics. Clinical training during fellowship is in movement disorders.
University of Virginia
Delaney Fisher is an American Heart Association Pre-Doctoral Fellow pursuing her Ph.D. in the Department of Biomedical Engineering at the University of Virginia. Her research in the Price Lab centers on leveraging the non-invasive, therapeutic technology of focused ultrasound to overcome challenges in treating disorders of the brain. Specifically, her dissertation work bridges the fields of biomedical engineering, neuroscience, and radiology to develop MRI-guided focused ultrasound platforms for the treatment of cerebral cavernous malformation, a disease that causes hemorrhagic, vascular growths in the brain. Previously, Delaney received her B.S. in Chemical and Biomolecular Engineering from the University of Tennessee.
Jessica Foley, PhD
Chief Scientific Officer; Managing Director, Cancer Immunotherapy Program and Government Affairs
Focused Ultrasound Foundation
Jessica Foley, PhD is the Chief Scientific Officer and a Managing Director for the Focused Ultrasound Foundation, whose mission is to accelerate the development and adoption of focused ultrasound, a breakthrough noninvasive therapeutic medical technology. Dr. Foley guides strategy, development, and implementation of scientific and research programs for the Foundation, and aligns these with business operations, communications, and development activities. She leads alliance-building efforts with external stakeholders including governmental policymakers, regulatory agencies, and disease-specific foundations whose interests are complementary to those of the Foundation. She is a spokesperson and advocate for the Foundation and the focused ultrasound community among a wide variety of stakeholders. Prior to the Foundation she spent several years in the medical device industry (Insightec, Medtronic) and was a AAAS Science and Technology Policy Fellow at the National Science Foundation. She holds a BSE in Biomedical Engineering from Duke University and a PhD in Bioengineering from the University of Washington.
Robert Friedlander, MD
University of Pittsburgh Medical Center
Dr. Robert M. Friedlander is Chair of the Department of Neurological Surgery and Walter E. Dandy Distinguished Professor at the University of Pittsburgh School of Medicine. Clinically, Dr. Friedlander specializes on the management complex cerebrovascular lesion, brain tumors and Chiari Malformations. Scientifically, he was first to slow Huntington’s disease and ALS in mice and has focused his career on delineating and manipulating caspase and mitochondrial cell death pathways. Dr. Friedlander is an elected member of the National Academy of Medicine, ASCI and AAP and prior member of the NINDS Advisory Council. He graduated with a BA and MA from Brandeis University, MD from Harvard Medical School and completed Neurosurgery residency at MGH. Prior to being recruited to Pittsburgh, Dr. Friedlander was Vice Chair of Neurosurgery at the Brigham and Women’s Hospital and Professor at Harvard Medical School.
Catherine Gorick, PhD
University of Virginia
Senior research scientist at the University of Virginia studying targeted gene delivery to the endothelium with focused ultrasound.
Yutong Guo, MSc
Dr. Yutong Guo is a postdoctoral scholar at Stanford University. Her research is focused on ultrasound-actuated microbubble dynamics and the induced immuno-mechano-biological effects, with the overarching goal of developing effective targeted cell and gene therapy against brain diseases. Her research approach involves the integration of computational modeling that supports the rational design of focused ultrasound-based treatment and quantitative imaging.
Justin Hanes, PhD
Professor; Director, Center for Nanomedicine
Johns Hopkins University School of Medicine
Justin Hanes is the Lewis J Ort Professor at the Johns Hopkins School of Medicine, where he directs the Center for Nanomedicine. He is a member of the National Academy of Medicine and the National Academy of Inventors. His research is focused on the development of new methods for improved drug and gene delivery to various locations in the body. He has collaborated with Prof. Rich Price of UVA for nearly 20 years on projects related primarily to the use of MRgFUS / microbubbles to enhance tissue-specific delivery of unique non-viral gene delivery systems, especially to the brain.
Guosong Hong, PhD
Dr. Guosong Hong received his Ph.D. in chemistry from Stanford University and completed postdoctoral training at Harvard University. Dr Hong joined Stanford Materials Science and Engineering and Wu Tsai Neurosciences Institute as an assistant professor in September 2018. His research at Stanford aims to develop novel optical and electronic materials for minimally invasive brain interfacing. He is a recipient of the NIH Pathway to Independence Award, the MIT Technology Review ‘35 Innovators Under 35’ Award, the Science PINS Prize for Neuromodulation, the NSF CAREER Award, the Walter J. Gores Award for Excellence in Teaching, and the Rita Allen Foundation Scholars Award.
Zhimin Huang, PhD
I am a postdoc from Dr. Szablowski’s lab at Rice University. More recently, we have developed a novel therapeutic paradigm called Regionally Activated Interstitial Drugs (RAID), enabling noninvasive and non-genetic neuromodulation and therapy of specific brain regions (Huang, et al. bioRxiv 2023.10.12.562069). My long-term research goal is to develop technologies for the noninvasive control and monitoring of endogenous signaling pathways in intact brain cells and tissues, with the aim of advancing brain treatment and neuroscience discovery.
Victor Jeannot, PhD
Victor Jeannot was born in France in 1983. He holds a Pharm.D and a Ph.D. in biotechnology (University Grenoble Alpes – France) and is specialized in the development of theranostic solutions. He joined Bracco Suisse SA in 2016 (Geneva, Switzerland) to manage the therapeutic ultrasound Lab. He led projects using gas microbubble for therapeutic application including gene delivery. In 2023 he became R&D Program Manager of Bracco Suisse managing a portfolio of innovation projects (Imaging – Therapy and Software development).
Postdoctoral Research Scientist
Robin Ji is an associate research scientist at Columbia University working on focused ultrasound mediated blood brain barrier opening for the delivery of biologics, including the delivery of AAVs for gene editing applications.
Yun Jing, PhD
Pennsylvania State University
Yun Jing received his B.S. degree in acoustics from Nanjing University, China, in 2006 and his Ph.D. degree from Rensselaer Polytechnic Institute in 2009 with a focus on architectural acoustics. He is currently a professor in the Graduate Program in Acoustics at Penn State University. Prior to joining Penn State University in 2020, he was a research fellow at Brigham and Women’s Hospital during 2009-2011, and an assistant professor and associate professor at North Carolina State University during 2011-2019. He is broadly interested in acoustic functional materials, biomedical ultrasound, nonlinear acoustics, and noise control. He has published over 100 peer-reviewed scientific manuscripts. He is a fellow of the Acoustical Society of America and a senior member of IEEE. He has received numerous awards such as the 2018 R. Bruce Lindsay Award from the Acoustical Society of America, the 2018 IEEE Ultrasonics Early Career Investigator award, 2018 MIT Technology Review Innovator under 35 China award, and the IEEE UFFC Star Ambassador Lectureship Award
Michael Kaplitt, PhD, MD
Professor of Neurological Surgery
Vice Chairman for Research, Residency Program Director
Weill Cornell Medical College
Rikke Kofoed, PhD
Rikke H Kofoed is post doc at Aarhus University and Aarhus University Hospital, Denmark. She has a biochemical background in neurodegenerative diseases and for the past 5 years (while mainly being at Sunnybrook Research Institute, Toronto, Canada) her research has focused on establishing and fine-tuning gene delivery strategies to the brain using focused ultrasound and microbubbles.
Elisa Konofagou, PhD
Elisa E. Konofagou is the Robert and Margaret Hariri Professor of
Biomedical Engineering and Professor of Radiology as well as Director of
the Ultrasound and Elasticity Imaging Laboratory at Columbia University in
New York City. Her main interests are in the development of novel elasticity
imaging techniques and therapeutic ultrasound methods and more
notably focused ultrasound in the brain for drug delivery and modulation,
breast tumor ablation monitoring with harmonic motion imaging,
myocardial elastography, electromechanical wave imaging, pulse wave
imaging with several clinical collaborations in the Columbia Presbyterian
Medical Center and beyond.
Jeffrey Kordower, PhD
Professor & Director, ASU-Banner Neurodegenerative Disease Research Center
Arizona State University
Jeffrey Kordower is the founding director of the ASU-Banner Neurodegenerative Disease Research Center and endowed chair as The Charlene and J. Orin Edson Distinguished Director at the Biodesign Institute at ASU. He has been a pioneer in the field of neural transplantation techniques and his pathbreaking investigations into the underpinnings of neurodegenerative disease have made him a leader in the field. Kordower’s interests include the study of gene and stem cell therapies, disease pathogenesis including the morphological and molecular changes during the course of neurodegeneration, learning and memory, and aging. He has also been a pioneer in the field of neural transplantation techniques. He comes to ASU from the Rush University Medical Center in Chicago, where he was faculty member for more than 30 years.
Hongyi (Richard) Li
California Institute of Technology
Richard Li is a senior PhD candidate in Biology at Caltech supervised by Professor Mikhail Shapiro. HIs research centers upon noninvasive surveillance and perturbation of neural circuits to study brain functions and to treat disorders in central nervous system. Li is currently focusing on engineering viral vectors for acoustically targeted gene transfer to achieve noninvasive, site-specific, cell type-specific, ultrasound-mediated genetic material delivery to the brain in various animal models. His long-term research goal is to develop primary/translational technologies for nonintrusive, real-time in vivo gene circuit monitoring and interfering in the brain through integration of biomolecular ultrasound, synthetic biology, tissue engineering, and vector engineering.
Shibi Likhite, MD
Nationwide Children’s Hospital
Shibi Likhite, MD is a Research Scientist at the Nationwide Children’s Hospital in Columbus, Ohio with over 14 years of experience in the fields of gene and cell therapy, as well as in vitro disease modeling. His work is focused on the development of novel tools for the translation of gene and cell therapy to human clinical trials, for treatment of both pediatric and adult-onset fatal diseases in the areas of neuromuscular, neurodegenerative, neurological, metabolic disorders and cancer. So far, Dr. LIkhite has been able to translate 5 gene therapy programs to the clinic and one program (Zolgensma® – onasemnogene abeparvovec) to the market with multiple other gene and cell therapy treatments in the pipeline. I have extensive experience in viral vector development and delivery with comprehensive knowledge of vector biology, rational design, vector manufacturing, and analytics required for efficacy and safety studies that are required for translation to the clinic. He has worked with multiple collaborators and industry partners on the key aspects of gene therapy such as vector development, manufacturing and vector delivery, notably AveXis-Novartis, Alcyone Therapeutics etc. Dr. Likhite also has expertise in utilizing CRISPR/Cas gene editing technology for development of off-the-shelf Chimeric Antigen Receptor expressing Natural Killer or T cell therapy (CAR-NK/CAR-T). Besides the gene and cell therapy work, he also has extensive experience in the cell-based model systems for studying the disease mechanisms and high-throughput screening of potential therapeutics.
David Lockhart, PhD
Dr. Lockhart is an accomplished biotech executive with more than 25 years of experience across all phases of drug discovery, drug development and technology development. Prior to becoming president and CSO of ReCode Therapeutics in January 2022, he served as CEO and president of the company since March 2020. Prior to serving as CEO and president of ReCode, he was CEO and president of its predecessor, TranscripTx from 2014 – 2020. Prior to TranscripTx, he was the Chief Scientific Officer at Amicus Therapeutics from 2006 through 2013. He led a team at Amicus that brought multiple rare disease programs into clinical trials. Previously, he co-founded Ambit Biosciences, serving as Chief Scientific Officer and president for 5 years, during which the company developed a novel kinase profiling technology and new kinase inhibitors for cancer and other diseases. Prior to Ambit, Dr. Lockhart served as Director of Genomics at the Genomics Institute of the Novartis Research Foundation (GNF). Dr. Lockhart began his biotech career at Affymetrix, where he was the primary inventor and developer of gene expression profiling with DNA microarrays. Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute in the Biology Department at MIT. He has published more than 80 peer-reviewed scientific articles on pharmacological chaperones, mutation-specific selection of patients for clinical trials, clinical studies with pharmacological chaperones, genomics, kinase technology, kinase inhibitor discovery, and the use of genomic tools to address important biological and biomedical problems. He is also the inventor on more than 40 issued U.S. patents.
Arthur Lung, PhD
Dr. Lung holds MSc and PhD degrees in Biomechanics from the University of Wisconsin-Madison and National Yang-Ming University, respectively. He has over 25 years of medical device product design, development, marketing, and selling experience, which has translated into 24 product launches during his career at United Orthopedic and Medtronic. He also has extensive entrepreneurship experience in the healthcare industry.
Subha Maruvada, PhD
US Food and Drug Administration, Center for Devices & Radiological Health
Dr. Maruvada is the lead for the Therapeutic Ultrasound Program in the Division of Applied Mechanics which is a part of the Office of Science and Engineering Laboratories. With a background in Electrical and Acoustical Engineering and Acoustics, Dr. Maruvada has worked in the area of acoustics measurements and modeling for over 20 years. Her current areas of research are pre-clinical characterization of high-intensity therapeutic ultrasound (HITU) devices, characterization of tissue-mimicking materials for HITU applications, Ultrasound-induced bioeffects, and comparison of acoustics measurements to modeling results. Dr. Maruvada is active in providing physics and engineering consults for FDA regulatory staff for HITU, Lithotripsy, Physiotherapy, and Diagnostic Ultrasound devices. Dr. Maruvada is active in both scientific and standards organizations. She serves as Working Group Convener, primary liaison and technical expert on several working groups within International Electrotechnical Commission (IEC) Technical Committee (TC) 87 Ultrasonics and has led the development of an international standard the field specifications and methods of measurements for low frequency ultrasound physiotherapy devices within IEC/TC 87. Dr. Maruvada is also the Past Vice-President of the Acoustical Society of America.
Nathan McDannold, PhD
Research Director, FUS Program
Brigham and Women’s Hospital
Dr. McDannold is a Physicist in Radiology Department at Brigham and Women’s Hospital and the Director of the Focused Ultrasound Laboratory. His work has been primarily concerned with the development and implementation of targeted drug delivery, ablation, and other focused ultrasound therapies, and methods to guide and monitor these therapies. He has also worked on clinical implementation of focused ultrasound.
Kathrin Meyer, PhD
Nationwide Children’s Hospital
Kathrin C. Meyer, PhD, studied Cellular and Biomedical Sciences at the Institute of Cell Biology in Berne, Switzerland. Her post-doctoral research was performed in Brian Kaspars laboratory at the Center for Gene Therapy in Columbus Ohio. During that time, Dr. Meyer established a new and fast reprogramming method for in vitro modeling of neurodegenerative diseases using patient skin cells. Moreover, Dr. Meyer developed intrathecal gene therapy programs for several neurodegenerative diseases including Spinal Muscular Atrophy and Batten Disease. Multiple clinical trials that are based on this work are currently ongoing at Nationwide Children’s Hospital. In 2017, Dr. Meyer became a Principal Investigator at Nationwide Children’s Hospital. She is also an Assistant Professor in the Department of Pediatrics at The Ohio State University, Columbus, Ohio.
Chrit Moonen, PhD
Scientific Programs Director
Following his studies in biophysics at Wageningen University, Chrit Moonen did a postdoctoral period at the University of Oxford (Sir Georg Radda). He joined UC Davis as a Visiting Research Scientist before becoming head of the NIH In Vivo NMR Research Center from 1987-1996. He was director of the laboratory “Molecular and Functional Imaging: from Physiology to Therapy” in Bordeaux until 2011. He was professor at the Division of Imaging at the University Medical Center in Utrecht, the Netherlands from 2011-2022. He recently joined the FUS Foundation as Scientific Programs Director.
Bernie Owusu-Yaw, PhD
Brigham and Women’s Hospital
Bernie obtained her PhD in Neuroscience from the UCL Institute of Prion Diseases at University College London. During her PhD she developed mouse models of a rare inherited form of prion disease to investigate the molecular mechanisms underlying the pathogenesis of this disease. She then went to do a post-doc at the UCL Institute for Women’s Health. There, she was involved in developing and testing novel gene therapies using different genetic models of paediatric epilepsy. She is currently a postdoctoral research fellow in the Focused Ultrasound Lab at Brigham and Women’s hospital. Her current work is centred on using focused ultrasound and microbubbles for AAV delivery in preclinical models of Huntington’s disease.
Frederic Padilla, PhD
Director of Gene and Cell Therapy Program
Focused Ultrasound Foundation
Frederic Padilla, PhD, is the Director of the Gene and Cell Therapy Program at the FUS Foundation. He joined the FUS Foundation in 2017 as a Merkin Fellow. Simultaneously, Frederic oversees the Foundation’s initiatives in applied physics and preclinical research, with a specific focus on advancing the potential of focused ultrasound to enhance immunotherapies for breast and pancreatic cancers. Before joining the Foundation, Frederic served as an Associate Professor at the French CNRS. He holds a Doctorate in Applied Physics from the University of Paris and an engineering degree from Centrale-Supelec. Frederic’s academic background includes a Fulbright Fellowship at Boston University and a Visiting Professorship at the University of Michigan.
Marie-Ève Paquet, PhD
Neurophotonics Centre, University of Laval
Dr. Marie-Eve Paquet has developed and is Head of the CERVO Brain Research Centre Vectorology platform within the Canadian Optogenetics and Vectorology Foundry. She is an adjunct professor in the department of biochemistry, microbiology and bioinformatics at the faculty of science and engineering at Université Laval in Quebec City Canada. In this role she oversees the strategic direction and operation of the largest viral vector facility in Canada. She also runs a research lab with interests in micro biome, molecular tools, optogenetics and optimisation of viral vector based gene transfer approaches. She has secured millions in external funding for research and research Infrastructure. Her group has strong collaborative ties with various tools developers and industries and distributes more than 1000 vectors yearly to over 250 research groups across the world.
Ramasamy Paulmurugan, PhD
Stanford University School of Medicine
Dr. Ramasamy Paulmurugan is a Professor in Radiology at Stanford University School of Medicine. He received his Masters in Biomedical Genetics and PhD in Molecular Virology from the University of Madras, India. After serving as a scientist for four years, he joined the School of Medicine at University of California, Los Angeles (UCLA) as a visiting scientist. In 2003, he moved to Stanford as a Senior Research Scientist. Since 2009, he has been a faculty in the Department of Radiology at Stanford University under the Molecular Imaging Program (MIPS) and Canary Center for Cancer Early Detection. He is a pioneer in developing split-reporter protein complementation systems for different reporter genes (luciferases, fluorescent proteins, and thymidine kinase), and has been using them for imaging cellular protein-protein interactions in living animals. Currently, his lab (Cellular Pathway Imaging Laboratory (CPIL)) is working on the application of different imaging strategies to evaluate the therapeutic role of ER, another important estrogen receptor, which is recently identified as one of the major players in estrogen biology. Other applications where his lab currently applying these assays include studying protein-protein interactions involved in estrogen receptor signaling, Nrf2-mediated antioxidant signaling in chemoresistance, p53-sumoylation mediated chemotherapy responses in cancer, NFkB mediated cytokine signaling in cancer, and signaling mechanisms associated with APP and Tau protein sumoylations in Alzheimer’s disease. In cancer therapy, his lab established microRNA-based reprogramming approaches to sensitizing drug-resistant cancers. In synthetic biology, his lab recently invented the application of a high-pressure microfluidic system in the reconstruction of biomolecules derived from cells (proteins and lipids) along with synthetic sources (phospholipids, polymers, and surfactants) to develop self-assembled nano- and micro-structures that mimic biological membranes for drug and microRNA delivery applications. As part of this process, his group developed biomimetic microbubbles (biMBs) and nanobubbles (biNBs) using tumor cell derived exosomes (TDEs) for cancer immunotherapy and imaging.
José Pineda-Pardo, PhD, MD
Centro Integral de Neurociencias HM Cinac
José Pineda is a dedicated researcher with a diverse background in engineering and biomedical sciences. He holds a degree in Telecommunications and Robotics Engineering and earned his Ph.D. in Biomedical Engineering from the Universidad Politécnica de Madrid. José’s research career has taken him through a remarkable journey across various institutions, including renowned organizations like the Fraunhofer Institute, universities, and more recently, hospital institutions. Currently, as a full-time researcher at hmCINAC, José Pineda is actively involved in two prominent research avenues. The first focuses on the development of image-based biomarkers for the early diagnosis of Parkinson’s disease, a critical area with significant implications for patient care and treatment. His work in this field seeks to provide innovative solutions for the early detection and management of this condition. The second major area of José’s research revolves around the development of therapeutic strategies for Parkinson’s disease patients using Focused Ultrasound. These strategies encompass a range of approaches, including thermoablation, blood-brain barrier disruption and drug-delivery, and neuromodulation.
Richard Price, PhD
University of Virginia
Richard J. Price, PhD, is the Nancy and Neal Wade Endowed Chair Professor of Biomedical Engineering and Professor of Radiology & Medical Imaging at the University of Virginia. He is also Co-Director of the UVa Focused Ultrasound Cancer Immunotherapy Center. He has been studying ultrasound-targeted drug and gene delivery for ~20 years. He was amongst the first investigators to observe that interactions between contrast agent microbubbles and ultrasound can be used to open endothelial barriers for targeted nanoparticle delivery, with emphasis on delivery across the blood-brain barrier. Recent studies entail using this approach to treat infiltrative gliomas and brain metastases, as well as for reversing neurodegeneration in Parkinson’s Disease. Dr. Price is also studying how focused ultrasound can synergize with various immunotherapeutic approaches, with his research in this area supporting clinical trials at UVA combining focused ultrasound with chemo- and immunotherapy for multiple cancer indications (NCT04796220, NCT03237572 and NCT04116320). Dr. Price has received the Andrew J. Lockhart Memorial Award for Focused Ultrasound Cancer Research, the Jorge Heller Award for Outstanding Original Research Paper in the Journal of Controlled Release, and the Gerritsen Award for most highly cited review article from the Microcirculatory Society. He is a Fellow of the American Institute of Medical and Biological Engineering and the Controlled Release Society. He has served on the Executive Council of the Microcirculatory Society and the ISTU Board of Directors.
Elizabeth Ramsburg, PhD
Dr. Ramsburg is an immunologist with many years experience in the development of vaccines and genetic medicines. Dr. Ramsburg began her academic career at Duke University where she was a member of the Duke Human Vaccine Institute and the Duke Virology Center. While at Duke Liz led a group aiming to develop vaccines and other countermeasures for emerging infections and HIV. In 2013 Liz joined Janssen Pharmaceuticals in the Netherlands, where she supported efforts to develop vaccines and gene therapies for neurodegenerative diseases. Liz joined Spark Therapeutics in 2021 as Head of Neuroscience Research where she manages all preclinical research within the Neuroscience therapeutic area.
Mark Schafer, PhD
Dr. Mark E. Schafer recently joined Drexel’s School of Biomedical Engineering, Science and Health Systems as a Research Professor. He has extensive expertise in ultrasound system development for medical applications, including combined ultrasound and therapeutic light sources for antibacterial treatment, as well as neurological applications of ultrasound. His experience includes diagnostic, therapeutic, and surgical ultrasound, as well as lithotripsy devices, from initial design, development and testing through regulatory submission and intellectual property protection. Dr. Schafer is PI on a just-awarded interdisciplinary Pennsylvania Commonwealth Universal Research Enhancement (CURE) grant (Co-PIs: Drs. Margaret Finley, College of Nursing and Health Professions; and Peter A. Lewin, School of Biomedical Engineering, Science and Health Systems).
Mikhail Shapiro, PhD
California Institute of Technology
Mikhail Shapiro is the Max Delbrück Professor of Chemical Engineering and Medical Engineering, an HHMI Investigator, and Director of the Center for Molecular and Cellular Medicine at Caltech. The Shapiro laboratory develops biomolecular technologies allowing cells to be imaged and controlled inside the body using sound waves and magnetic fields. These technologies enable the study of biological function in vivo and the development of cell-based diagnostic and therapeutic agents. Mikhail received his PhD in Biological Engineering from MIT and his BSc in Neuroscience from Brown. He conducted post-doctoral research at the University of Chicago and the University of California, Berkeley, where he was a Miller Fellow. Mikhail’s awards include the NIH Pioneer Award, the Packard Fellowship, the Pew Scholarship, the Sontag Foundation Distinguished Scientist Award, the Camille Dreyfus Teacher-Scholar Award, the Carl Hellmuth Hertz Ultrasonics Award and the Roger Tsien Award for Excellence in Chemical Biology. Mikhail serves a co-founder and scientific advisory board member to several venture-backed startups in biotechnology and medical devices. More information about the Shapiro Lab can be found online at https://shapirolab.caltech.edu.
Khadijeh Sharifi, PhD
University of Virginia
I obtained my PhD degree in Neuroscience in 2017 from the Tehran University of Medical Sciences (TUMS), Tehran, Iran. My doctorate thesis was “GABA-endocannabinoid interactions in the dorsal hippocampus and basolateral amygdala mediated morphine-induced amnesia”. I presented several lectures on neurobiology of learning and memory and the interactions of hippocampus with other brain regions during state dependent learning. During my PhD, I was responsible for planning and teaching classes and tutoring other people in the lab. I also worked several months in Graz, Austria as a Practical Training Internship (PTI) with Dr. Manfred Windisch, PhD to expand my scientific research skills. Following my graduation, I accepted a postdoctoral fellowship position at the University of Virginia (UVA). This new position gave me an excellent opportunity to improve and extend my neuroscience training in the field of neurogenesis and regeneration in ischemic stroke as well as other neurological dysfunctions. Currently, I have a full-time position as a postdoctoral research fellow, in the department of Neuroscience and Neurosurgery. My work with Dr. Petr Tvrdik is centered on the role of Wnt signaling in stroke-induced neurogenesis and the mechanisms through which the Wnt pathway regulates regeneration and repair after injury. In addition, I have contributed to several other neurological projects such as novel ultrasound treatment for cerebral cavernous malformations and live imaging studies of peri-infarct spreading depolarizations and depressions.
Natasha Sheybani, PhD
University of Virginia
Natasha Sheybani, Ph.D. is an Assistant Professor of Biomedical Engineering and (by courtesy) of Radiology & Medical Imaging and Neurosurgery at the University of Virginia. She also serves as Research Director of UVA’s Focused Ultrasound Cancer Immunotherapy Center. Dr. Sheybani leads a translational research program centered on investigating the use of focused ultrasound for immuno-modulation and immunotherapy delivery in solid tumors. Her research also interfaces with multiple ongoing clinical investigations of FUS for breast and brain cancer treatment at UVA (NCT03237572, NCT04796220, NCT06039709). She was UVA’s first-ever recipient of the NIH Director’s Early Independence Award and has formerly held the NSF Graduate Research Fellowship, Robert R. Wagner Fellowship, and NCI F99/K00 Predoctoral-to-Postdoctoral Fellow Transition Award. Dr. Sheybani completed her Ph.D. in Biomedical Engineering at UVA and her postdoctoral fellowship in Oncology, Biomedical Data Science and Radiology at Stanford University. She has been recognized by health news website STAT as a “Wunderkind” and was recently elected to Forbes Magazine’s “30 Under 30” List in Science.
Courtney Silverthorn, PhD
Foundation for the National Institutes of Health
Dr. Courtney Silverthorn is an Associate Vice President for Science Partnerships at the Foundation for the National Institutes of Health (FNIH). With extensive experience in public-private partnerships and federal technology transfer policy, she serves as the Director of the Accelerating Medicines Partnership® (AMP®) program and is responsible for new business development in platform approaches to therapeutics and the program’s Bespoke Gene Therapy Consortium, a multi-year public-private partnership to advance manufacturing and regulatory frameworks for gene therapy treatments for rare diseases. Prior to joining the FNIH, Courtney was the Acting Director of the Technology Partnerships Office at the National Institute of Standards and Technology (NIST), where she led technology transfer activities at the agency and was central to the interagency Lab-to-Market initiative. She also held tech transfer and policy roles at the Office of Science and Technology Policy, the Frederick National Laboratory for Cancer Research, and the National Cancer Institute. Dr. Silverthorn earned a Ph.D. in Pharmacology from The Johns Hopkins University School of Medicine, a M.S. in Leadership from Washington University in St. Louis, and a B.S. in Biochemistry and Molecular Biology from Sweet Briar College.
Jared Smith, PhD
Jared B. Smith, PhD is a Principle Scientist in Research and Early Development at REGENXBIO, a clinical-stage AAV gene therapy company. His work focuses on the development of novel AAV gene therapy approaches to neurodegenerative, neuromuscular, and epileptic diseases, as well as the development of novel technologies to improve gene transfer capabilities. He received his PhD in neuroscience from the Penn State College of Medicine in 2013 and postdoctoral training at the Salk Institute for Biological Studies before joining RGNX in 2019.
Robert Smith, BSc, MBA
Senior Vice President, Global Gene Therapy Business
Bob is the Senior Vice President, Global Gene Therapy Business at Pfizer since May 2016. He is an accomplished biopharmaceutical executive with over thirty-five years’ experience in a variety of alliance management, business development, commercial, corporate, and research and development leadership roles. Bob is responsible for leading Pfizer’s Global Gene Therapy Business including the strategic and operational development and implementation of Pfizer’s end-to-end, enterprise-wide efforts to be the industry leader in gene therapy.
Prior his current role, Bob was responsible for leading and managing the Worldwide Business Development activities for Pfizer’s Worldwide Research and Development organization as well as Pfizer’s Strategic Transactions team. During his tenure at Pfizer, Bob also had responsibility for leading and managing the business development and strategy teams for Pfizer’s Animal Health, Capsugel, Consumer Healthcare and Nutrition Business Units and the Alliance Management function supporting Pfizer’s Biopharmaceutical Business Units and the Worldwide Research and Development organization.
Bob joined Pfizer from Wyeth in October 2009, following Pfizer’s acquisition of Wyeth, where he was responsible for leading and managing Wyeth’s Global Mergers and Acquisitions group. He was also responsible for the global mergers and acquisitions activities for Wyeth’s Consumer Healthcare division and its Fort Dodge Animal Health division. Prior to this role, Bob was Senior Vice President, Global Licensing, Wyeth Pharmaceuticals, where he completed a wide variety of transactions in support of Wyeth’s commercial and research and development divisions.
Bob serves or has served as a member of the Board of Directors of AM Pharma B.V., Bamboo Therapeutics Inc., Ignite Immunotherapeutics Inc., Iterum Therapeutics Limited, Life Sciences PA – the Pennsylvania Biotechnology Association, Bio NJ – the New Jersey State Biotechnology Association, the Duke Margolis Value Based Agreements Advisory Board, the Alliance for Regenerative Medicine (ARM) and the Foundation for Cell and Gene Medicine (FCGM). He is also a member of the Executive Committees of the ARM and FCGM Board of Directors and he serves as the Chairman of the ARM Board’s Governance and Operations Committee. Bob is a member of the Investment Advisory Committee for Venture Investors LLC, Madison, Wisconsin. He also serves on the Focused Ultrasound Foundation’s Gene Therapy Scientific Advisory Board.
Bob obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Business Administration at the University of Rochester, Rochester, New York.
Tao Sun, PhD
Tao Sun is an Assistant Professor of Bioengineering and a core member of Institute of Chemical Imaging of Living Systems (CILS) at Northeastern University. He joined Northeastern in January 2023 after postdoctoral trainings from Brigham and Women’s Hospital and Harvard Engineering School (Bioengineering), and an Instructor role with Harvard Medical School. Tao has received many recognitions for his scientific contributions to the fields of focused ultrasound, drug delivery, cancer immunoengineering, and neuroimaging. He is a recipient of the Young Investigator Awards from Focused Ultrasound Foundation (2022) and Acoustical Society of America (2021).
Kelsie Timbie, PhD
Veterinary Medicine Program Director; Scientific Programs Manager
Focused Ultrasound Foundation
Kelsie Timbie, PhD joined the Foundation in 2015. As the Scientific Programs Manager, she is responsible for developing and guiding research projects that address critical unmet needs and will further the Foundation’s mission of widespread clinical adoption of this technology. As the Director of the Veterinary Program, she is responsible for guiding and developing the scope of the program. She is also involved in managing the research portfolios of the Cancer Immunotherapy and Brain Programs here at the Foundation, as her extensive research experience in brain and cancer applications for focused ultrasound provides her with particular insight in these areas. Kelsie earned her BS in Chemical Engineering from Clarkson University and her PhD in Biomedical Engineering from the University of Virginia.
Nicholas Todd, PhD
Brigham and Women’s Hospital
Dr. Todd is an Assistant Professor in the Department of Radiology at Brigham and Women’s Hospital and Harvard Medical School. His research uses the tools of focused ultrasound and magnetic resonance imaging to develop treatments for neurological disorders.
Petr Tvrdik, PhD
University of Virginia Health System
Petr Tvrdik received his BS and PhD from the Charles University and the Academy of Sciences of the Czech Republic. Following postdoctoral training at Stockholm University, Sweden, he joined the group of Mario Capecchi at the University of Utah. He used the transformative gene targeting technology, developed by the Capecchi laboratory, to study the role of Hox genes in brainstem development and hematopoiesis. He also participated in an interdepartmental effort
to develop genetically encoded reporters of neural and glial activity in mouse and rat models of neurological disease. After joining the faculty of Neurosurgery and Neuroscience at the University of Virginia as Academic Investigator, Dr. Tvrdik employs genetically encoded indicators to study the role of microglial calcium signaling in mouse models of ischemic stroke and molecular underpinnings of common vascular diseases such as cerebral cavernous malformations.
Yingxiao “Peter” Wang, PhD
Chair of the Department of Biomedical Engineering
University of Southern California
Dr. Wang received his Ph.D. degree in Bioengineering from the University of California, San Diego Jacobs School of Engineering in 2002 and continued his postdoctoral work at UC San Diego working under Bioengineering Professor Shu Chien and Professor Roger Y. Tsien in the Department of Pharmacology. Before joining the UC San Diego faculty in 2012, he was a faculty at the University of Illinois, Urbana-Champaign (UIUC), Department of Bioengineering and the Beckman Institute for Advanced Science and Technology. Dr. Wang is the recipient of the Wallace H. Coulter Early Career Award (both Phase I and Phase II), the National Science Foundation CAREER Award, and National Institutes of Health Independent Scientist Award. His research is aimed at the integration of the cutting-edge technologies to develop molecular biosensors with their colors tunable by local biochemical signals. These biosensors can be introduced into living cells to monitor and report the dynamic intracellular biochemical signals with high spatial resolutions, which can advance our systematic and in-depth understanding of how cells coordinate molecular signals in response to environmental cues. He also applies these biosensors to detect abnormal molecular signals for cancer diagnosis and prognosis, with the ultimate goal of enhancing the health and well-being of humankind.
Zezhuang Ye, PhD
Washington University in St. Louis
Dr. Ye earned her Ph.D. in Mechanical Engineering from Washington University in Saint Louis in 2021, where she worked under the guidance of Prof. Hong Chen. Currently, she holds a postdoctoral associate position in Dr. Chen’s lab, extending her research within the fields of Biomedical Engineering and Radiation Oncology. During her Ph.D. studies, Dr. Ye concentrated on developing Focused Ultrasound (FUS)-mediated brain drug delivery techniques aimed at treating various brain diseases. She developed Focused Ultrasound-mediated Intranasal (FUSIN) brain drug delivery, overcoming a significant clinical challenge—the restricted access of drugs to the brain due to the blood-brain barrier with minimized systemic exposure. In her current role, Dr. Ye is dedicated to integrating FUS-mediated brain drug delivery techniques into gene therapy as a potential treatment for neurodegenerative diseases. Additionally, she is exploring the effects of FUS on glymphatic transportation, further contributing to our understanding of brain health and disease.
Nisi Zhang, PhD
Nisi Zhang received her PhD degree in Biomedical Engineering from Peking University in 2022. Her PhD work focused on the development of nanosonosensitizers and conducting sonodynamic therapy in murine cancer models. Nisi joined the Ferrara lab at Stanford University as postdoctoral scholar in 2022 and is currently working on ultrasound-mediated gene transfection for cancer immunotherapy using microbubbles and lipid nanoparticles..